Titan Medical Inc. (TMDIF) Stock Analysis
DELISTED 2024
What happened to Titan Medical Inc. (TMDIF) stock?
Titan Medical Inc. (TMDIF) no longer trades on public markets. It was delisted in October 2024. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Titan Medical Inc. (TMDIF) trades at $0.8175. Titan Medical Inc. is a medical technology company focused on developing and licensing robotic-assisted surgical technologies. Market cap: $13.9M, Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for TMDIF: TMDIF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TMDIF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
TMDIF: the 2 scored disciplines are evenly split. Dominant signal: Izzy Englander bearish.
How is this calculated? →Titan Medical Inc. (TMDIF) Healthcare & Pipeline Overview
Titan Medical Inc., based in Toronto, Canada, operates as a medical technology company, concentrating on the development and licensing of robotic-assisted surgical technologies. With a small team and a focus on innovation, the company aims to carve a niche in the competitive medical devices market.
What Is the Investment Thesis for TMDIF?
Titan Medical Inc. presents a speculative investment opportunity within the robotic-assisted surgery market. With a market capitalization of $13.9M and a P/E ratio of 13.34, the company's valuation reflects its early stage and potential for growth. A key value driver is the company's intellectual property in robotic surgical technology, which could generate revenue through licensing agreements. Growth catalysts include securing partnerships with established medical device companies and achieving regulatory approvals for its technologies. Potential risks include the company's small size, limited operating history, and intense competition in the medical device industry. Investors should carefully consider these factors when evaluating Titan Medical's investment potential.
Based on FMP financials and quantitative analysis
TMDIF Key Highlights
Market Cap of $13.9M indicates a micro-cap company with high growth potential but also higher risk.
- P/E ratio of 13.34 suggests the company is potentially undervalued compared to its earnings, but this should be viewed cautiously given the company's size and industry.
- Gross Margin of 100.0% reflects a licensing-focused business model with minimal direct costs of goods sold.
- Profit Margin of 39.4% demonstrates efficient operations and strong profitability from its licensing activities.
- Beta of 1.98 indicates high volatility compared to the market, reflecting the speculative nature of the stock.
Who Are TMDIF's Competitors?
TMDIF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ATBPF Antibe Therapeutics Inc. | $0.22 | -0.19% | $11.4M | 44 |
| EIGRQ Eiger BioPharmaceuticals, Inc. | $8.50 | +6.25% | $12.6M | 54 |
| LXXGF LexaGene Holdings Inc. | $0.08 | +0.00% | $11.3M | 53 |
| MNNDF Nurosene Health Inc. | $0.33 | -8.71% | $14.3M | 46 |
| VPTDF VentriPoint Diagnostics Ltd. | $0.07 | -4.02% | $13.8M | 62 |
| CNVIF Conavi Medical Corp. | $0.13 | -1.19% | $11.4M | 66 |
| LHDX Lucira Health, Inc. | $0.45 | +0.00% | $18.4M | 64 |
| PLSM PLSM | $3.01 | +4.88% | $19.6M | 60 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TMDIF's Key Strengths?
Innovative robotic surgical technology.
- Strong intellectual property portfolio.
- High gross profit margin.
- Potential for strategic partnerships.
What Are TMDIF's Weaknesses?
Small company size and limited resources.
- Dependence on licensing revenue.
- Limited operating history.
- OTC market listing.
What Could Drive TMDIF Stock Higher?
Potential partnerships with established medical device companies could drive revenue growth.
- Regulatory approvals for its robotic surgical technologies in key markets.
- Continuous development and licensing of new robotic surgical technologies.
- Expansion of applications into new therapeutic areas.
- Exploration of international markets beyond North America.
What Are the Key Risks for TMDIF?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Intense competition from established players in the medical device industry.
- Technological obsolescence could render its technologies outdated.
- Regulatory hurdles and delays in obtaining approvals.
- Dependence on licensing revenue makes it vulnerable to changes in market demand.
- Small company size and limited resources may hinder its ability to compete effectively.
What Are the Growth Opportunities for TMDIF?
- Growth opportunity 1: Securing strategic partnerships with established medical device companies represents a significant growth opportunity for Titan Medical. By partnering with larger companies, Titan Medical can leverage their distribution networks, regulatory expertise, and financial resources to accelerate the commercialization of its robotic surgical technologies. Timeline: Ongoing.
- Growth opportunity 2: Expanding the applications of its robotic-assisted surgical technologies into new therapeutic areas represents another key growth opportunity for Titan Medical. By adapting its platform for use in different surgical specialties, such as cardiology, orthopedics, and neurology, the company can broaden its addressable market and increase its revenue potential. The market for minimally invasive surgery is expanding rapidly, driven by the desire for reduced patient trauma, shorter hospital stays, and faster recovery times. Timeline: Ongoing.
- Growth opportunity 3: Obtaining regulatory approvals for its robotic surgical technologies in key markets, such as the United States and Europe, is essential for Titan Medical's long-term growth. Regulatory approvals would validate the safety and efficacy of its technologies, paving the way for commercialization and adoption by healthcare providers. The regulatory approval process can be lengthy and expensive, but it is a necessary step for accessing these large and lucrative markets. Timeline: Upcoming.
- Growth opportunity 4: Developing and licensing new robotic surgical technologies represents a continuous growth opportunity for Titan Medical. By investing in research and development, the company can create innovative solutions that address unmet needs in the surgical market. The medical device industry is characterized by rapid technological advancements, and companies that can consistently innovate and develop new products are best positioned for long-term success. Timeline: Ongoing.
- Growth opportunity 5: Exploring international markets beyond North America offers a significant growth opportunity for Titan Medical. By expanding its geographic reach, the company can tap into new customer bases and diversify its revenue streams. The demand for robotic surgery is growing globally, particularly in emerging markets with rapidly developing healthcare systems. Entering new markets requires careful planning and execution, but it can provide a significant boost to Titan Medical's growth prospects. Timeline: Ongoing.
What Are TMDIF's Competitive Advantages?
- Proprietary robotic surgical technology.
- Intellectual property protection through patents.
- Potential for strategic partnerships with established players.
- First-mover advantage in specific niche applications.
What Does TMDIF Do?
Titan Medical Inc., headquartered in Toronto, Canada, is a medical technology company dedicated to the advancement of robotic-assisted surgical technologies. The company focuses on research, development, and licensing of innovative solutions designed to enhance surgical precision and patient outcomes. While the company's founding story is not detailed in the provided data, its current operations revolve around creating intellectual property and seeking strategic partnerships for commercialization. Titan Medical's core business model involves developing robotic surgical platforms and licensing these technologies to larger medical device companies or healthcare providers. The company's geographic reach is primarily focused on North America, with potential for global expansion through licensing agreements. Titan Medical competes with established players in the robotic surgery market, such as Intuitive Surgical, as well as other emerging companies in the medical device space. Titan Medical aims to differentiate itself through technological innovation and strategic partnerships.
What Products and Services Does TMDIF Offer?
- Develops robotic-assisted surgical technologies.
- Focuses on minimally invasive surgical solutions.
- Creates intellectual property in the medical device field.
- Seeks licensing agreements for its technologies.
- Aims to improve surgical precision and patient outcomes.
- Operates in the healthcare sector, specifically medical devices.
How Does TMDIF Make Money?
- Develops robotic surgical platforms.
- Licenses its technologies to medical device companies.
- Generates revenue through licensing fees and royalties.
What Industry Does TMDIF Operate In?
Titan Medical Inc. operates within the medical devices industry, a sector characterized by rapid technological advancements and increasing demand for minimally invasive surgical procedures. The robotic surgery market is projected to experience significant growth, driven by factors such as an aging population, rising prevalence of chronic diseases, and the desire for improved surgical outcomes. Titan Medical faces competition from established players like Intuitive Surgical and other emerging companies developing innovative surgical technologies. The company's success depends on its ability to secure regulatory approvals, establish strategic partnerships, and effectively commercialize its robotic-assisted surgical technologies.
Who Are TMDIF's Key Customers?
- Medical device companies seeking innovative surgical technologies.
- Hospitals and healthcare providers adopting robotic surgery.
- Patients benefiting from minimally invasive surgical procedures.
Company Profile
Titan Medical Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Toronto, CA. The company is led by CEO Thomas Looby. TMDIF has traded publicly since 2010.
How Titan Medical Inc. Is Valued
Titan Medical Inc. carries a market capitalization of $13.9M, placing it in the micro-cap category.
Key Financial Metrics
Return on assets is 79.8%, showing how much profit it generates from its asset base. TMDIF trades at a trailing price-to-earnings ratio of 13.74, below the Healthcare sector average of ~23x. Its free cash flow yield is 32.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.78 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 7.3%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Titan Medical Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
TMDIF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Titan Medical's recent strategic shift towards collaborative development could open doors to faster innovation and market entry, echoing strategies seen in successful biotech partnerships. Insider activity suggests confidence in the long-term vision, a sentiment often mirrored before significant company milestones. Community buzz highlights the potential of their Enos robotic system to disrupt the surgical landscape, similar to Intuitive Surgical's early days. Positive market perception, driven by successful trial outcomes, could attract further investment and partnerships, fueling growth.
Bear Case
- The medical device sector is fiercely competitive, and Titan Medical faces established players with significant resources, a challenge akin to smaller EV companies competing with Tesla. Community sentiment reveals concerns about funding and potential dilution, reminiscent of anxieties surrounding cash-strapped startups. Bearish views question the speed of regulatory approvals and market adoption for the Enos system, a hurdle many innovative medical devices face. Market perception reflects skepticism about the company's ability to scale production and distribution efficiently, a common pitfall for emerging medical technology firms.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
TMDIF Latest News
No recent news available for TMDIF.
Leadership: Thomas Looby
CEO
Thomas Looby serves as the CEO of Titan Medical Inc., leading a small team of four employees. Information regarding his detailed career history, education, and previous roles is not available in the provided data. However, as CEO, he is responsible for the strategic direction and overall management of the company.
Track Record: Due to the limited information available, it is difficult to assess Thomas Looby's specific achievements and strategic decisions at Titan Medical. His leadership is focused on guiding the company's development and licensing of robotic-assisted surgical technologies.
TMDIF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Titan Medical Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Investing in OTC Other stocks carries a higher degree of risk compared to stocks listed on major exchanges like the NYSE or NASDAQ due to the lack of regulatory oversight and potential for illiquidity.
- OTC Tier: OTC Other
- Limited financial disclosure increases information asymmetry.
- Low trading volume and liquidity can lead to price volatility.
- Higher potential for fraud and manipulation compared to listed exchanges.
- OTC Other stocks may be subject to less regulatory oversight.
- Difficulty in obtaining accurate and timely information about the company.
- Verify the company's registration and legal standing.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Research the background and experience of the management team.
- Understand the risks associated with investing in OTC stocks.
- Monitor trading volume and price activity.
- Consult with a financial advisor before investing.
- Company operates in a legitimate sector (medical devices).
- Company has a registered headquarters in Canada.
- Company has a CEO and management team.
- Company has a business model focused on technology development and licensing.
- Company has intellectual property in the form of robotic surgical technology.
Common Questions About TMDIF (Healthcare)
What happened to Titan Medical Inc. (TMDIF) stock?
Titan Medical Inc. (TMDIF) no longer trades on public markets. It was delisted in October 2024. The figures below are historical and are not a current quote.
Can I still buy TMDIF shares?
No. TMDIF stopped trading on public markets in October 2024, so the shares are not available through a broker. Anything you see quoted for TMDIF elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before TMDIF stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Titan Medical Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Titan Medical Inc. do?
Titan Medical Inc. operates as a medical technology company focused on the development and licensing of robotic-assisted surgical technologies. The company aims to improve surgical precision and patient outcomes through its innovative robotic platforms. Titan Medical generates revenue by licensing its technologies to medical device companies and healthcare providers, allowing them to integrate these advancements into their surgical procedures.
What are the main risks for TMDIF?
Titan Medical Inc. faces several risks inherent to its position as a small, OTC-listed medical device company. Intense competition from larger, more established players in the robotic surgery market poses a significant threat. The company's dependence on licensing revenue makes it vulnerable to changes in market demand and the success of its partners.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on CEO background and track record.
- AI analysis is pending, so some sections are based on limited data.
- OTC market stocks carry higher risk.